OptimizeRx Corp
corporate_fare Company Profile
OptimizeRx Corp (NASDAQ:OPRX) is a publicly traded company in the Trade & Services sector. Wiseek has independently scored 17 items for OPRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for OPRX spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- OptimizeRx 10-Q: Q3 Revenue Down 17%, Net Income $1.2M, Material Weakness Persists
- OptimizeRx Cuts FY26 Revenue Guidance to $87-$93M Despite Q3 EBITDA Beat
- OptimizeRx Posts 20c Adjusted EPS for Third Quarter
- OptimizeRx CFO Stelmakh to Exit; D'Silva and Favazza Promoted; Q2 Revenue Falls 30%
- OptimizeRx Q2 Revenue Falls 30% to $20.5M, Reaffirms FY26 Guidance
Financial Snapshot
Short Interest & Short Volume
9.75 days to coverFINRA reported short interest of 1,187,196 shares in OPRX as of the October 30, 2026 settlement, a 10.1% increase from the prior period — about 9.8 days to cover at its recent average daily volume. On November 20, 2026, 54.2% of OPRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.